Tags

Type your tag names separated by a space and hit enter

Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Metabolism. 2006 Apr; 55(4):439-44.M

Abstract

To evaluate the effects of rosiglitazone (ROS) on serum adiponectin and C-reactive protein (CRP) in nonobese subjects with impaired glucose tolerance (IGT), we enrolled 21 patients with body mass index < or =24 kg/m(2) to receive ROS 4 mg daily for 12 weeks. Fifteen age-, sex-, and body mass index-matched healthy subjects were recruited as controls. A 75-g oral glucose tolerance test (OGTT), hemoglobin A(1c), fasting glucose, insulin, C-peptide, lipid profiles, adiponectin, and CRP levels were determined before initiation and at the end of the 12-week ROS treatment. Insulin resistance and beta-cell function were calculated using the homeostasis model assessment method (HOMA-IR and HOMA-beta, respectively). Compared with healthy controls, the ROS-treated subjects had significantly higher glycemic indices, HOMA-IR, CRP, and glucose and insulin concentrations in response to OGTT, and lower HOMA-beta level. After 12 weeks of ROS therapy, the results showed statistically significant changes from baseline in 2-hour plasma glucose during OGTT (9.4 +/- 0.3 vs 8.3 +/- 0.4 mmol/L, P < .05), HOMA-IR (2.6 +/- 0.2 vs 1.9 +/- 0.3, P < .05), HOMA-beta (63.4 +/- 12.5 vs 90.1 +/- 13.0, P < .05), and glucose and insulin concentrations during OGTT in nonobese subjects with IGT. In addition, elevation of serum adiponectin and decrease in CRP levels were significantly found after ROS treatment. Of 21 patients treated with ROS, 5 subjects were converted to normal (converter), 1 progressed to diabetes, and 15 remained in IGT status (nonconverter). There was a significant amelioration in HOMA-IR (-2.10 +/- 1.03 vs -0.07 +/- 0.33, P < .05) without significant changes in adiponectin and CRP levels in converter compared with nonconverter. We conclude that ROS effectively enhanced insulin sensitivity and beta-cell function to improve adiponectin and CRP levels in nonobese patients with IGT. The amelioration of insulin resistance may be a major determinant to predict the conversion of IGT independent of the changes in adiponectin and CRP.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, ROC. metahung@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

16546473

Citation

Hung, Yi-Jen, et al. "Rosiglitazone Improves Insulin Sensitivity in Nonobese Subjects With Impaired Glucose Tolerance: the Role of Adiponectin and C-reactive Protein." Metabolism: Clinical and Experimental, vol. 55, no. 4, 2006, pp. 439-44.
Hung YJ, Lin SH, Pei D, et al. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism. 2006;55(4):439-44.
Hung, Y. J., Lin, S. H., Pei, D., Kuo, S. W., Hsieh, C. H., He, C. T., Hsing Lee, C., Fan, S. C., & Sheu, W. H. (2006). Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism: Clinical and Experimental, 55(4), 439-44.
Hung YJ, et al. Rosiglitazone Improves Insulin Sensitivity in Nonobese Subjects With Impaired Glucose Tolerance: the Role of Adiponectin and C-reactive Protein. Metabolism. 2006;55(4):439-44. PubMed PMID: 16546473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. AU - Hung,Yi-Jen, AU - Lin,Shih-Hua, AU - Pei,Dee, AU - Kuo,Shi-Wen, AU - Hsieh,Chang-Hsun, AU - He,Chih-Tsueng, AU - Hsing Lee,Chien, AU - Fan,Sandra Chyi, AU - Sheu,Wayne Huey-Herng, PY - 2005/04/14/received PY - 2005/10/17/accepted PY - 2006/3/21/pubmed PY - 2006/5/4/medline PY - 2006/3/21/entrez SP - 439 EP - 44 JF - Metabolism: clinical and experimental JO - Metabolism VL - 55 IS - 4 N2 - To evaluate the effects of rosiglitazone (ROS) on serum adiponectin and C-reactive protein (CRP) in nonobese subjects with impaired glucose tolerance (IGT), we enrolled 21 patients with body mass index < or =24 kg/m(2) to receive ROS 4 mg daily for 12 weeks. Fifteen age-, sex-, and body mass index-matched healthy subjects were recruited as controls. A 75-g oral glucose tolerance test (OGTT), hemoglobin A(1c), fasting glucose, insulin, C-peptide, lipid profiles, adiponectin, and CRP levels were determined before initiation and at the end of the 12-week ROS treatment. Insulin resistance and beta-cell function were calculated using the homeostasis model assessment method (HOMA-IR and HOMA-beta, respectively). Compared with healthy controls, the ROS-treated subjects had significantly higher glycemic indices, HOMA-IR, CRP, and glucose and insulin concentrations in response to OGTT, and lower HOMA-beta level. After 12 weeks of ROS therapy, the results showed statistically significant changes from baseline in 2-hour plasma glucose during OGTT (9.4 +/- 0.3 vs 8.3 +/- 0.4 mmol/L, P < .05), HOMA-IR (2.6 +/- 0.2 vs 1.9 +/- 0.3, P < .05), HOMA-beta (63.4 +/- 12.5 vs 90.1 +/- 13.0, P < .05), and glucose and insulin concentrations during OGTT in nonobese subjects with IGT. In addition, elevation of serum adiponectin and decrease in CRP levels were significantly found after ROS treatment. Of 21 patients treated with ROS, 5 subjects were converted to normal (converter), 1 progressed to diabetes, and 15 remained in IGT status (nonconverter). There was a significant amelioration in HOMA-IR (-2.10 +/- 1.03 vs -0.07 +/- 0.33, P < .05) without significant changes in adiponectin and CRP levels in converter compared with nonconverter. We conclude that ROS effectively enhanced insulin sensitivity and beta-cell function to improve adiponectin and CRP levels in nonobese patients with IGT. The amelioration of insulin resistance may be a major determinant to predict the conversion of IGT independent of the changes in adiponectin and CRP. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/16546473/Rosiglitazone_improves_insulin_sensitivity_in_nonobese_subjects_with_impaired_glucose_tolerance:_the_role_of_adiponectin_and_C_reactive_protein_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(05)00403-8 DB - PRIME DP - Unbound Medicine ER -